Company Overview
CureVac N.V. operates as a biopharmaceutical entity dedicated to developing transformative medicines based on messenger ribonucleic acid (mRNA) technology for various diseases. The company functions within the Healthcare sector, specifically inside the Biotechnology industry, where its focus is on the research and development of novel therapeutic candidates. As of December 18, 2025, the company was acquired by BioNTech SE, marking a significant shift in its corporate structure and operational independence. In terms of scale, CureVac N.V. holds a market capitalization of $1.05B, generated annual revenue of $70.74M, and employs 825 individuals. These valuation and revenue figures indicate that the company possesses a substantial asset base relative to its earnings, suggesting a position that combines significant historical R&D investment with a relatively compact revenue stream typical of biotechnology firms in development phases.
Financial Health
CureVac N.V. reported revenue of $70.74M over the trailing twelve months (TTM), with a net income of $128.82M and an EBITDA of $193.69M. The gap between the $70.74M revenue and the $128.82M net income reveals a cost structure where operating expenses and tax impacts are negative, resulting in earnings that exceed total revenue, a phenomenon often seen in accounting adjustments or specific non-operating income events within the biotech sector. The company's free cash flow is listed as N/A, indicating that the specific metrics regarding cash generation relative to capital expenditures are not currently disclosed in the available data, which limits the assessment of immediate financial flexibility. The gross margin stands at 93.3%, while the operating margin is reported at 573.0%, and the profit margin reaches 182.1%. These margin levels, particularly the operating and profit margins exceeding 100%, suggest that the reported net income includes significant non-operating gains or specific accounting treatments that inflate profitability beyond the direct cost of goods sold. On the balance sheet, the company holds $416.09M in cash against $35.07M in debt, resulting in a debt-to-equity ratio of 4.03. This leverage metric indicates a capital structure heavily reliant on equity financing rather than debt, though the high ratio warrants attention regarding long-term solvency. The current ratio is 3.70, which indicates a strong short-term liquidity position where current assets significantly exceed current liabilities. Return on Equity and Return on Assets are listed as N/A, meaning these specific return metrics are not available for analysis; consequently, the traditional assessment of management effectiveness relative to equity or asset bases cannot be calculated from the provided figures.
Valuation Assessment
The trailing P/E ratio is 6.96, while the forward P/E is -8.02, implying that the market expects earnings to decline or be negative in the future based on forward projections. The price-to-book ratio is 0.83, indicating that the company trades at a discount to its book value, suggesting the market values the firm below the replacement cost of its assets. The price-to-sales ratio is 14.83, and the EV/EBITDA is 2.39; these alternative valuation metrics suggest that the company is priced at a premium relative to its sales but at a low multiple of its earnings before interest, taxes, depreciation, and amortization. The 52-week high is $5.72 and the 52-week low is $2.48, placing the current trading range within a specific band relative to this historical volatility. The beta value is 1.84, which means the stock price exhibits high volatility relative to the broader market, moving with significantly greater intensity than the market average.
Growth & Income
The revenue growth year-over-year is -89.0%, whereas the earnings growth year-over-year is 24.0%, indicating that earnings are growing faster than revenue. This divergence implies that non-revenue factors such as cost reductions, asset sales, or one-time gains are driving the reported earnings increase despite a sharp contraction in sales. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all earnings into growth initiatives, R&D, or balance sheet strengthening rather than distributing cash to shareholders. The overall growth and income profile reflects a capital-intensive biotechnology model where earnings are decoupled from revenue due to accounting anomalies or restructuring, and where shareholder returns are driven by potential acquisition value or future cash flow generation rather than current payouts.